Spots Global Cancer Trial Database for Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
Official Title: A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies
Study ID: NCT00831896
Conditions
Interventions
Study Description
Brief Summary: This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharmacokinetics profile of TAK-701.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Name: Medical Monitor
Affiliation: Millennium Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
